mrg001
mAbexperimentalADC
Clinical trial activity
6 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Jun 25, 2019 (NCT05155839)
Timeline
Indications
Studied for
- Amyotrophic Lateral Sclerosis · Phase 2
- Atrophy · Phase 2
- COVID-19 · Phase 1/Phase 2
- Cytokine Release Syndrome · Phase 2
- Dermatology · Phase 2
- Hepatitis, Alcoholic · Phase 2
- Lymphoma, Non-Hodgkin · Phase 1
- Motor Neuron Disease · Phase 2
- Regeneration · Phase 1/Phase 2
- Respiratory Distress Syndrome · Phase 2
- Respiratory Insufficiency · Phase 2
- Respiratory Tract Diseases · Phase 2
- Stem Cells · Phase 1/Phase 2
- Wounds and Injuries · Phase 2
Mechanism of action
- B-lymphocyte antigen CD20BINDING AGENT
CD20
Chemistry & pharmacology
- Payload
- Monomethyl auristatin E
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06315608 | Phase 2 | Jul 1, 2025 | MedRegen LLC |
| NCT06308926 | Phase 2 | Dec 1, 2024 | MedRegen LLC, Vanderbilt University |
| NCT06307522 | Phase 2 | Sep 1, 2024 | MedRegen LLC |
| NCT05844527 | Phase 2 | Nov 20, 2023 | MedRegen LLC, Northwestern University |
| NCT04646603 | Phase 1/Phase 2 (Phase 2) | Jan 28, 2021 | ICON, MedRegen LLC |
| NCT05155839 | Phase 1 | Jun 25, 2019 | Peking University, Shanghai Miracogen Inc. |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| MedRegen LLC | For profit | 5 | 5 | 1 | 2021 |
| ICON | For profit | 1 | 0 | 1 | 2021 |
| Northwestern University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Shanghai Miracogen Inc. | For profit | 1 | 1 | 1 | 2019 |
| Vanderbilt University | Academic/Hospital | 1 | 0 | 1 | 2024 |
6 organizations
Page 1 / 1